One of a new wave of treatments, Novartis has focused on proving its drug cuts vaso-occlusive crises (VOCs), or pain crises.
The US Food and Drug Administration approved on 15 November Novartis’s Adakveo, a new treatment to reduce vaso-occlusive crises (VOCs), or pain crises in sickle cell disease.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.
Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.
A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.
